Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma.

Irreversible electroporation (IRE) is an innovative local-regional therapy that involves delivery of intense electrical pulses to tissue to induce nanoscale cell membrane defects for tissue ablation. The purpose of this study was to investigate the feasibility of using IRE as a liver-directed ablation technique for the treatment of hepatocellular carcinoma (HCC). In the N1-S1 rodent model, hepatomas were grown in 30 Sprague-Dawley rats that were divided into treatment and control groups. For treatment groups, IRE electrodes were inserted and eight 100-mus 2,500-V pulses were applied to ablate the targeted tumor tissues. For both groups, magnetic resonance imaging scans were performed at baseline and 15-day follow-up intervals to determine tumor sizes (one-dimensional maximum diameter, D(max); estimated two-dimensional cross-sectional area, C(max)) as a tactic to assess longitudinal outcomes. Additional groups of treated animals were sacrificed at 1-, 3-, and 7-day intervals posttherapy for pathology assessment of treatment response. Magnetic resonance images showed significant tumor size reductions within 15 days posttherapy (32 +/- 31% D(max) and 52 +/- 39% C(max) decreases compared with 110 +/- 35% D(max) and 286 +/- 125% C(max) increases for untreated tumors). Pathology correlation studies documented progression from poorly differentiated viable HCC tissues before treatment to extensive tumor necrosis and full regression in 9 of 10 treated rats 7 to 15 days after treatment. Our findings suggest that IRE can be an effective strategy for targeted ablation of liver tumors, prompting its further evaluation for HCC therapy.

[1]  J. Hinshaw,et al.  Cryoablation for liver cancer. , 2007, Techniques in vascular and interventional radiology.

[2]  P. Foubert,et al.  Integrin α4β1 signaling is required for lymphangiogenesis and tumor metastasis (Cancer Research (2010) 70, (3042-51) DOI , 2010 .

[3]  W. Lau,et al.  The Current Role of Radiofrequency Ablation in the Management of Hepatocellular Carcinoma: A Systematic Review , 2009, Annals of surgery.

[4]  M. Najimi,et al.  Hepatocyte apoptosis. , 2009, Methods in molecular biology.

[5]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[6]  J. F. Burrows,et al.  Tumor and Stem Cell Biology Cancer Research The Deubiquitinating Enzyme USP 17 Is Highly Expressed in Tumor Biopsies , Is Cell Cycle Regulated , and Is Required for G 1S Progression , 2010 .

[7]  C. Croce,et al.  Oncogenic role of miR-483-3p at the IGF2/483 locus. , 2010, Cancer research.

[8]  J. Charboneau,et al.  Technologies for ablation of hepatocellular carcinoma. , 2008, Gastroenterology.

[9]  J. Bruix,et al.  Novel advancements in the management of hepatocellular carcinoma in 2008. , 2008, Journal of hepatology.

[10]  Carlo Bartolozzi,et al.  Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. , 2005, Radiology.

[11]  H. Gaylord,et al.  AMERICAN ASSOCIATION FOR CANCER RESEARCH. , 1913, California state journal of medicine.

[12]  H. Fukuda,et al.  European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .

[13]  P. Liang,et al.  Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. , 2005, Radiology.

[14]  A. Novikoff,et al.  A transplantable rat liver tumor induced by 4-dimethylaminoazobenzene. , 1957, Cancer research.

[15]  Yun Liang,et al.  Technical aspects of imaging and transfemoral arterial treatment of N1-S1 tumors in rats: an appropriate model to test the biology and therapeutic response to transarterial treatments of liver cancers. , 2009, Journal of vascular and interventional radiology : JVIR.

[16]  Wang Qi,et al.  Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma in Elderly Patients , 2009 .

[17]  P. Fisher,et al.  Molecular mechanism of chemoresistance by astrocyte elevated gene-1. , 2010, Cancer research.

[18]  T. Kawabe,et al.  Radiofrequency ablation for hepatocellular carcinoma in so‐called high‐risk locations , 2006, Hepatology.

[19]  Wei Lu,et al.  Tumor Site–Specific Silencing ofNF-κB p65by Targeted Hollow Gold Nanosphere–Mediated Photothermal Transfection , 2010, Cancer Research.

[20]  D Miklavcic,et al.  A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy. , 2000, Biochimica et biophysica acta.

[21]  Boris Rubinsky,et al.  Cancer Cells Ablation with Irreversible Electroporation , 2005, Technology in cancer research & treatment.

[22]  Boris Rubinsky,et al.  Tumor Ablation with Irreversible Electroporation , 2007, PloS one.

[23]  M Deimling,et al.  Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: technique and prospective results. , 1995, Radiology.

[24]  M. Varma,et al.  Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature , 2005, Histopathology.

[25]  J. Benoit,et al.  Description and technical pitfalls of a hepatoma model and of intra-arterial injection of radiolabelled lipiodol in the rat , 2005, Laboratory animals.

[26]  A. Burroughs,et al.  Hepatocellular carcinoma , 2003, The Lancet.

[27]  G. Mills,et al.  Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. , 2010, Cancer research.

[28]  H. Rhim Complications of radiofrequency ablation in hepatocellular carcinoma , 2005, Abdominal Imaging.

[29]  S. M. Lobo,et al.  Improved coagulation with saline solution pretreatment during radiofrequency tumor ablation in a canine model. , 2002, Journal of vascular and interventional radiology : JVIR.

[30]  Boris Rubinsky,et al.  Optimal parameters for the destruction of prostate cancer using irreversible electroporation. , 2008, The Journal of urology.

[31]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[32]  J. Bruix,et al.  Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma , 1992, Hepatology.

[33]  Boris Rubinsky,et al.  Irreversible Electroporation: Implications for Prostate Ablation , 2007, Technology in cancer research & treatment.

[34]  W. Lu,et al.  Tumor site-specific silencing of NF-κB p65 by targeted hollow gold nanosphere-mediated photothermal transfection (Cancer Research (2010) 70, (3177-3188) DOI: 10.1158/0008-5472.CAN-09-3379) , 2010 .

[35]  J. Vincent,et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.

[36]  Jon F Edd,et al.  Mathematical Modeling of Irreversible Electroporation for Treatment Planning , 2007, Technology in cancer research & treatment.

[37]  J. Chien,et al.  Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. , 2010, Cancer research.

[38]  L. Mir,et al.  A Study of the Immunological Response to Tumor Ablation with Irreversible Electroporation , 2007, Technology in cancer research & treatment.

[39]  Boris Rubinsky,et al.  Irreversible Electroporation: A New Ablation Modality — Clinical Implications , 2007, Technology in cancer research & treatment.

[40]  T. Livraghi,et al.  Percutaneous Ethanol Injection in the treatment of hepatocellular carcinoma in cirrhosis. , 1998, Hepato-gastroenterology.

[41]  Boris Rubinsky,et al.  The Effect of Irreversible Electroporation on Blood Vessels , 2007, Technology in cancer research & treatment.

[42]  R. Hoffman,et al.  The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. , 2010, Cancer research.

[43]  A. Harris,et al.  Histological quantitation of tumour angiogenesis , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[44]  P. Hsu,et al.  Clinical trial: percutaneous acetic acid injection vs. percutaneous ethanol injection for small hepatocellular carcinoma – a long‐term follow‐up study , 2008, Alimentary pharmacology & therapeutics.

[45]  T. Schall,et al.  Tumor and Stem Cell Biology Cancer Research The Chemokine Receptor CXCR 7 Is Highly Expressed in Human Glioma Cells and Mediates Antiapoptotic Effects , 2010 .

[46]  Shinpei Sato,et al.  Percutaneous radiofrequency ablation for hepatocellular carcinoma , 2005, Cancer.

[47]  Adrian Fisher,et al.  Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. , 2003, Journal of the American College of Surgeons.

[48]  E F Halpern,et al.  Radio-frequency tissue ablation: effect of pharmacologic modulation of blood flow on coagulation diameter. , 1998, Radiology.

[49]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[50]  G. Gores,et al.  Caspase inhibition reduces apoptotic death of cryopreserved porcine hepatocytes , 2001, Hepatology.

[51]  H. Rhim,et al.  Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies , 2009, Hepatology.

[52]  J. F. Burrows,et al.  The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression. , 2010, Cancer research.

[53]  A. Muotri,et al.  Coordination of centrosome homeostasis and DNA repair is intact in MCF-7 and disrupted in MDA-MB 231 breast cancer cells. , 2010, Cancer research.

[54]  Jing Ma,et al.  Immunohistochemical expression of BRCA1 and lethal prostate cancer. , 2010, Cancer research.

[55]  B. Rubinsky,et al.  Tissue Ablation with Irreversible Electroporation , 2005, Annals of Biomedical Engineering.

[56]  M. Kloor,et al.  Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers. , 2010, Cancer research.

[57]  Boris Rubinsky,et al.  Temperature considerations during irreversible electroporation , 2008 .

[58]  Chris T. Harvey,et al.  ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. , 2010, Cancer research.

[59]  J. Chien,et al.  Downregulation of HtrA 1 Promotes Resistance to Anoikis and Peritoneal Dissemination of Ovarian Cancer Cells , 2010 .

[60]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[61]  W R Lees,et al.  Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. , 2000, Radiographics : a review publication of the Radiological Society of North America, Inc.

[62]  Boris Rubinsky,et al.  In vivo results of a new focal tissue ablation technique: irreversible electroporation , 2006, IEEE Transactions on Biomedical Engineering.

[63]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[64]  Stephen T Kee,et al.  Imaging Guided Percutaneous Irreversible Electroporation: Ultrasound and Immunohistological Correlation , 2007, Technology in cancer research & treatment.

[65]  T. Livraghi,et al.  Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. , 1995, Radiology.

[66]  J. Heath,et al.  Signal transducers and activators of transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplification. , 2010, Cancer research.

[67]  H. Kung,et al.  Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. , 2010, Cancer research.